Skip to main content

Table 3 Mean change from baseline in TSS and subscores in the DMARD-IR population as estimated with meta-analysis

From: Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis

 

Week 12

Week 24

Week 52

Week 104

CFB

95 % CrI

Probability of deterioration relative to baseline

CFB

95 % CrI

p-value

CFB

95 % CrI

Probability of deterioration relative to baseline

CFB

95 % CrI

Probability of deterioration relative to baseline

TSS

 DMARDs

1.14

(0.66, 1.67)

>0.99

2.27

(1.31, 3.34)

>0.99

4.92

(2.84, 7.23)

>0.99

9.84

(5.68, 14.46)

>0.99

 MTXa

0.97

(0.49, 1.52)

0.99

1.95

(0.98, 3.05)

0.99

4.22

(2.13, 6.6)

0.99

8.44

(4.26, 13.21)

0.99

 AZAa

2.16

(2.16, 3.04)

>0.99

4.32

(2.59, 6.07)

>0.99

9.35

(5.62, 13.15)

>0.99

18.70

(11.24, 26.31)

>0.99

Erosion Subscore

 DMARDs

0.51

(0.27, 0.83)

0.99

1.02

(0.55, 1.66)

0.99

2.22

(1.19, 3.6)

0.99

4.43

(2.38, 7.21)

0.99

 MTXa

0.43

(0.25, 0.69)

0.98

0.87

(0.49, 1.39)

0.98

1.88

(1.07, 3.01)

0.98

3.76

(2.14, 6.01)

0.98

 AZAa

1.31

(1.31, 1.98)

>0.99

2.62

(1.3, 3.96)

>0.99

5.67

(2.81, 8.57)

>0.99

11.35

(5.61, 17.14)

>0.99

Joint Space Narrowing Subscore

 DMARDs

0.36

(0.09, 0.67)

0.99

0.72

(0.18, 1.33)

0.99

1.57

(0.4, 2.89)

0.99

3.14

(0.80, 5.78)

0.90

  1. AZA azathioprine, CrI credible interval; DMARD disease-modifying anti-rheumatic drug; DMARD-IR patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to non-biologic DMARDs who are currently treated with one (other) non-biologic DMARD, CFB change from baseline; MTX methotrexate, p-value probability of joint structural deterioration relative to baseline; TSS modified Total Sharp Score
  2. aEstimated based on comparative data only, using models for relative treatment effects (see Model 3 and 4 in Additional file 2), which allows comparative interpretation of MTX and AZA findings